Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 18
Healthy volunteers: yes

Brief summary:
It is the objective of this MRD trial to investigate pharmacokinetics, pharmcodynamics, safety and tolerability of rising doses BI 691751 over a treatment period of 14 days to support the further clinical development of this LTA4H-inhibitor. Special emphasis will be given to detect potential effects of BI 691751 on heart rate.

Detailed description:

Arms:
arm 1: multiple dose given over 14 days arm 2: multiple dose given over 14 days arm 3: multiple dose given over 14 days arm 4: multiple dose given over 14 days arm 5: multiple dose given over 14 days arm 6: multiple dose given over 14 days arm 7: Placebo

Interventions: intervention 1: BI 691751 intervention 2: BI 691751 intervention 3: BI 691751 intervention 4: BI 691751 intervention 5: BI 691751 intervention 6: BI 691751 intervention 7: Placebo
Intervention descriptions: intervention 1: BI 691751 Dose 1 intervention 2: BI 691751 Dose 2 intervention 3: BI 691751 Dose 3 intervention 4: BI 691751 Dose 4 intervention 5: BI 691751 Dose 5 intervention 6: BI 691751 Dose 6 intervention 7: Placebo

Protocol document: